Ibrutinib Deacryloylpiperidine CAS 330786-24-8 Puritas >99.0% (HPLC)

Description:

Chemical Name: Ibrutinib Deacryloylpiperidine

CAS: 330786-24-8

Puritas: >99.0% (HPLC)

Aspectus: Off-White ad Khaki pulveris

Medium Ibrutinib (CAS: 936563-96-1)

Contactus: Dr

Mobile/Wechat/Whatsapp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Chemical Properties:

Nomen chemicum	3-(4-Phenoxyphenyl) -1H-pyrazolo[3,4-d] pyrimidin-4-amine
Synonyma	Ibrutinib intermeidato N-2;Ibrutinib Deacryloylpiperidine;Ibrutinib immunditia 8;5-(4-Phenoxyphenyl) -7H-pyrrolo[2,3-d]pyrimidin-4-ylamine;IBT4A;Ibrutinib N-Despiperidinyl Impurity
CAS Number	330786-24-8
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C17H13N5O
M. Pondus	303.32
Liquescens punctum	>262℃(dec.)
Density	1.380±0.06 g/cm3
Periculum Classis	6.1;Venenum
Stipare Group	III
COA & MSDS	Praesto
Origin	Shanghai, China
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Off-White ad Khaki pulveris
Lepidium sativum	HNMR, LC-MS
Puritas / Analysis Methodus	>99.0% (HPLC)
Damnum in Siccatio	<1.00%
Unius Max.immunditia	<1.00%
Totalis immunditias	<1.00%
Metalla gravia (ut Pb)	<20ppm
Test Standard	Enterprise Standard
Consuetudinem	Medium Ibrutinib (CAS: 936563-96-1)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.

commoda:

FAQ:

330786-24-8 - Applicatio:

3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (CAS: 330786-24-8) utilis synthetica media in synthesi Ibrutinib (CAS: 936563-96-1 ).Ibrutinib est genus tyrosine kinase bruton (BTK) inhibitoris, adhiberi potest ad curationem lymphocyticam longam leukemia (CLL) et pallium cellae lymphomae (MCL).MCL et CLL ad lymphoma B-celluli Hodgkin non pertinebant, quod difficile est curare et facile recurrere.Commune chemicum immunotherapyrum scopum non habet, saepe occurrit motus 3 vel 4 adversas.Ibrutinib et B lymphocytes oppugnare potuerunt cum BTK, quae ad informationem, differentiationem et transmissionem necessaria sunt, BTK actionem irreversibiliter inhibent, et tumorem cellularum proliferation et efficaciter superstes inhibent.Ibrutinib celeriter post administrationem oralis absorberi potuit, in 1~2h ad maximam unionem sanguinis, motus adversae unius vel duo pertinent, ergo Ibrutinib nova optio curationis CLL et MCL fiet.